Dan Ashley , acclaimed journalist and ABC-7 San Francisco Bay Area News anchor, will serve as the emcee for World AIDS Day. Honored with a park bench in the National AIDS Memorial Grove for his ...

GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.

According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...

On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.41 which represents a slight increase of $1.06 or 1.16% from the prior close of $91.35. The stock opened at ...

Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

Dr. Reddy’s Laboratories RDY announced that it has launched a biosimilar of Coherus BioSciences’ CHRS Loqtorzi (toripalimab) ...

While antiviral drugs to treat HIV had been approved a decade earlier, only five out of 33 million people who carried the ...

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene ...

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.